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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 11, Revision 3 
(FGE.11Rev3): Aliphatic dialcohols, diketones, and hydroxyketones from 
chemical groups 8 and 101 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate 11 flavouring substances in the Flavouring Group Evaluation 11, Revision 
3, using the Procedure in Commission Regulation (EC) No 1565/2000. The substances were evaluated through a 
stepwise approach (the Procedure) that integrates information on structure-activity relationships, intake from 
current uses, toxicological threshold of concern and available data on metabolism and toxicity. The present 
Revision of FGE.11, FGE.11Rev3, is prepared due to the evaluation of genotoxicity data, which have been 
requested in the previous version of FGE.11, for 3-methylnona-2,4-dione [FL-no: 07.184]. Additionally, new 
information on the stereoisomerism of [FL-no: 07.184 and 07.260] has become available. Based on the new data 
received the Panel concluded that all 11 flavouring substances [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 
07.167, 07.168, 07.184, 07.238, 07.248 and 07.260] do not give rise to safety concerns at their levels of dietary 
intake, estimated on the basis of the MSDI approach. Besides the safety assessment of these flavouring 
substances, the specifications for the materials of commerce have also been considered. Specifications including 
complete purity criteria and identity for the materials of commerce have been provided for all candidate 
substances. 
© European Food Safety Authority, 2014 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to deliver a scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 11 flavouring substances in the 
Flavouring Group Evaluation 11, Revision 3 (FGE.11Rev3), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. These 11 flavouring substances belong to chemical 
group 8 and 10, Annex I of the Commission Regulation (EC) No 1565/2000.  
The present flavouring group includes 11 candidate substances; eight alpha-diketones or their 
corresponding alcohols or ketals [FL-no: 02.133, 07.071, 07.152, 07.167, 07.168, 07.238, 07.248 and 
07.260] and three β-diketones or their corresponding β-hydroxyketones (of which one is a tertiary 
alcohol) [FL-no: 07.165, 07.097 and 07.184] all belonging to chemical groups 8 and 10. 
The present Revision of FGE.11, FGE.11Rev3, is prepared due to the evaluation of genotoxicity data, 
which have been requested in the previous version of FGE.11 for 3-methylnona-2,4-dione [FL-no: 
07.184]. Additionally, new information on natural occurrence in food [FL no: 07.165, 07, 184 and 
07.238] and on the stereoisomerism for [FL-no: 07.184 and 07.260] and composition for one 
substance [FL-no: 07.097] has become available. 
Two of the flavouring substances possesses two chiral centres [FL-no: 02.133 and 07.168] and five 
substances possesses one chiral centre [FL-no: 07.097, 07.167, 07.184, 07.238 and 07.260]. For all 
substances, the stereoisomeric composition has been specified sufficiently. 
Five of the flavouring substances are classified in structural class I, five in structural class II and one 
in structural class III.  
Nine of the flavouring substances in the present group have been reported to occur naturally in a wide 
range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach. 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the candidate substances have European intakes ranging 
from 0.0012 to 15 µg/capita/day, which are below the thresholds of concern for structural class I, II 
and III (1800, 540 and 90 µg/person/day, respectively). The total combined estimated levels of intake 
of candidate and supporting substances (all from structural class II) is approximately 4600 
µg/capita/day, which exceeds the threshold of concern for structural class II (540 µg/person/day). 
However, based on information on efficient metabolism and on presence in the body as endogenous 
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compounds, there are no safety concerns from the combined intakes of the candidate and supporting 
substances. 
Data available for the flavouring substance 3-methyl-2,4-nonadione [FL-no: 07.184] shows that this 
substance has no genotoxic potential in vitro. For the remaining flavouring substances in the present 
FGE, genotoxicity data are only available for a limited number, and the genotoxicity could not be 
assessed adequately. However, the genotoxicity data available do not preclude evaluation using the 
Procedure. 
The candidate flavouring substances in this FGE are expected to be metabolised to innocuous 
products. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that on the basis of the default MSDI approach the 11 candidate substances evaluated 
through the Procedure [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 07.184, 
07.238, 07.248 and 07.260] would not give rise to safety concerns at the estimated levels of intake 
arising from their use as flavouring substances. 
When the estimated intakes were based on the mTAMDI approach they ranged from 1600 to 3900 
µg/person/day for the five candidate substances from structural class I, from 1500 to 5400 µg/ 
person/day for the five candidate substances from structural II and for the one substance from 
structural class II the mTAMDI is 1600 µg/person/day. So for seven candidate substances evaluated 
through the Procedure [FL-no: 02.133, 07.071, 07.152, 07.168, 07.184, 07.248 and 07.260] the 
intakes, estimated on the basis of the mTAMDI exceed the threshold for the structural class, to which 
the flavouring substances have been assigned. Therefore, more reliable exposure data are required. On 
the basis of such additional data, the substances should be reconsidered along the steps of the 
Procedure. Following this procedure additional toxicological data might become necessary. In order to 
determine whether the conclusion for the candidate substances can be applied to the materials of 
commerce, it is necessary to consider the available specifications. Adequate specification and data on 
stereoisomerism are available for all the candidate substances.  
Thus, all 11 substances [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 07.184, 
07.238, 07.248 and 07.260] evaluated in the present FGE would not present any safety concern at the 
estimated levels of intake based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.6 
The Commission asks EFSA to evaluate this new information.  
EFSA has evaluated 12 flavouring substances in the Flavouring Group Evaluation 11 Revision 2 
(FGE.11Rev2). The Opinion was adopted on17 June 2009. EFSA concluded that the final evaluation 
could not be performed for the substance [FL-no: 07.184], further data on genotoxicity are required 
before it can be evaluated through the Procedure. 
The requested information on 3-methyl-2,4-nonadione [FL-no: 07.184] has now been submitted by the 
applicant.  
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substance. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests European Food Safety Authority (EFSA) to evaluate this new 
information and, depending on the outcome, proceed to the full evaluation on this flavouring substance 
in accordance with Commission Regulation (EC) No 1565/2000. 
                                                     
4 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p, 1-161. 
6 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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ASSESSMENT 
1. History of the evaluation of the substances in the present FGE  
The first version of the Flavouring Group Evaluation 11, FGE.11 dealt with six flavouring substances, 
α- and β-diketones, one related ketal, hydroxyketones, and diols. 
The first Revision of FGE.11, FGE.11Rev1 included the assessment of two additional candidate 
substances [FL-no: 07.238 and 07.260]. One flavouring substance, pentan-2,4-dione (former candidate 
substance [FL-no: 07.191]) was deleted from the Register of flavouring substances as it is considered 
genotoxic in vitro and in vivo. 
The second Revision of FGE.11, FGE.11Rev2, included the assessment of five additional candidate 
substances [FL-no: 06.134, 07.097, 07.168, 07.184 and 07.248]. The candidate substance 3-methyl-
2,4-nonadione [FL-no: 07.184] contains a structural 2,4-dione element which is considered 
genotoxic in vitro and in vivo. Due to the structural alert for genotoxicity the Procedure was not 
applied for 3-methyl-2,4-nonadione [FL-no: 07.184] and accordingly additional data on 
genotoxicity were required. For the candidate substance diacetyl trimer [FL-no: 06.134] additional 
metabolism and toxicity data were required. 
Since the publication of FGE.11Rev1 and the Minutes from the 7th Plenary meeting in which the 
conclusion on the FGE.11Rev2 was summarised, information on stereoisomeric composition and a 
boiling point has been provided by EFFA on the following six substances: [FL-no: 02.133, 07.097, 
07.167, 07.168, 07.238 and 07.260] (EFFA, 2010). 
FGE Opinion adopted 
by EFSA 
Link No. of 
candidate 
substances 
FGE.11 9 December 2004 http://www.efsa.europa.eu/en/efsajournal/doc/166.pdf 6 
FGE.11Rev1 17 April 2007 http://www.efsa.europa.eu/en/efsajournal/doc/493.pdf 7 
FGE.11Rev2 17 June 2009 http://www.efsa.europa.eu/en/efsajournal/pub/1170.htm 12 
FGE.11Rev3   11 
 
The present Revision of FGE.11, FGE.11Rev3, includes the re-evaluation of 3-methylnona-2,4-dione 
[FL.no: 07.184] as additional genotoxicity data (in vitro micronucleus) have been submitted (Watters, 
2013). A search in the open literature did not provide any further relevant data on toxicity or 
metabolism for the substance, but additional data on natural occurenec in food for [Fl-no: 07.165, 
07.184 and 07.238] was found and has been included. 
Information on stereoisomerism or on composition has been provided for three substances [FL-no: 
07.097, 07.184 and 07.260] (EFFA, 2014). These data are also included in the present revision. 
In addition, the publication of FGE.11Rev2, one of the 12 candidate substances is no longer supported 
by the Industry for use as flavouring substance in Europe (DG SANCO, 2012). The substance is 
diacetyl-trimer [FL-no: 06.134] and the substance will therefore not be considered any further. 
2. Presentation of the Substances in Flavouring Group Evaluation 11, Revision 3 
2.1. Description 
The present Flavouring Group Evaluation 11, Revision 3 (FGE.11Rev3), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (the Procedure – shown in schematic 
form in Appendix A), deals with eight α-diketones or their corresponding alcohols or ketal and one β-
diketone and two β-hydroxy ketones. These 11 flavouring substances (candidate substances) belong to 
chemical groups 8 and 10 of Annex I of Regulation (EC) No 1565/2000 (EC, 2000). 
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The 11 candidate substances under consideration in the present evaluation are listed in Table 1, as well 
as their chemical Register names, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of 
Europe- (CoE-) and Flavor and Extract Manufacturers Association- (FEMA-) numbers, structures and 
specifications. This group of candidate substances includes eight α-diketones or their corresponding 
alcohols or ketals [FL-no: 02.133, 07.071, 07.152, 07.167, 07.168, 07.238, 07.248 and 07.260], and 
three β-diketone or their corresponding alcohols (of which one is a tertiary alcohol) [FL-no: 07.097, 
07.165 and 07.184]. 
The outcome of the safety evaluation is summarised in Table 6. The hydrolysis products anticipated 
for the candidate ketals are listed in Table 7. 
The 11 candidate substances are closely related structurally to 13 aliphatic acyclic α-diketones and 
related α-hydroxyketones (supporting substances) evaluated at the 51st meeting of the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) in the group “Aliphatic acyclic and 
alicyclic α-diketones and related α-hydroxyketones” (JECFA, 1999a). The names and structures of the 
13 supporting substances are listed in Table 8, together with their evaluation status. 
2.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number, etc.). 
Two of the 11 candidate substances possess two chiral centres [FL-no: 02.133 and 07.168] and five 
substances possess one chiral centre [FL-no: 07.097, 07.167, 07.184, 07.238 and 07.260]. Adequate 
information on the stereoisomeric composition of these substances has been provided. 
Flavouring Group Evaluation 11 Revision 3
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 11, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility 
in ethanol 
(b) 
Boiling point, 
°C (c) 
Melting point, 
°C 
ID test 
Assay 
minimum 
Refrac. 
Index (d) 
Spec.gravity 
(e) 
Specification 
comments 
02.133 
 
Butane-2,3-diol 
OH
OH  
10181 
513-85-9 
Liquid 
C4H10O2 
90.12 
Soluble 
Freely 
soluble 
181 
 
MS 
95 % 
1.432-1.438 
1.001-1.007 
 
Racemate (EFFA, 2010). 
06.134 
 
Diacetyl-trimer O
O
O
O
HO
O
 
4303 
 
18114-49-3 
Solid 
C12H18O6 
258.27 
Soluble 
Soluble 
 
90 
MS 
95 % 
n.a. 
n.a. 
 
No longer supported by 
Industry, (DG SANCO, 
2012). Stereoisomeric 
composition not specified 
by CASrn in Register. 
Register name to be 
changed to: 1,1’-
(tetrahydro-6a-hydroxy-
2,3a,5-trimethylfuro[2,3-
d]-1,3-dioxole-2,5-
diyl)bis-ethanone. 
07.071 
 
Octane-4,5-dione 
O
O 4533 
2141 
5455-24-3 
Liquid 
C8H14O2 
142.20 
Slightly 
soluble 
Freely 
soluble 
168 
 
MS 
95 % 
1.415-1.421 
0.907-0.913 
 
 
07.097 
 
3-(Hydroxymethyl)octan-2-
one 
OH
O 3292 
11113 
59191-78-5 
Liquid 
C9H18O2 
158.24 
Slightly 
soluble 
Freely 
soluble 
80 (0.3 hPa) 
 
NMR 
92 % 
1.416-1.422 
0.874-0.878 
 
Racemate (EFFA, 2010). 
Min. Assay value 92 %, 
secondary component: 5 - 
7 % 3-methylene-2-
octanone (EFFA, 2014). 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 11, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility 
in ethanol 
(b) 
Boiling point, 
°C (c) 
Melting point, 
°C 
ID test 
Assay 
minimum 
Refrac. 
Index (d) 
Spec.gravity 
(e) 
Specification 
comments 
07.152 
 
3,3-Diethoxybutan-2-one 
O
O
O
 
 
51933-13-2 
Liquid 
C8H16O3 
160.21 
Slightly 
soluble 
Freely 
soluble 
164 
 
MS 
95 % 
1.400-1.406 
0.919-0.925 
 
 
07.165 
 
4-Hydroxy-4-methylpentan-
2-one 
O
OH
 
 
123-42-2 
Liquid 
C6H12O2 
116.16 
Slightly 
soluble 
Freely 
soluble 
165 
 
MS 
95 % 
1.418-1.424 
0.929-0.935 
 
 
07.167 
 
4-Hydroxyhexan-3-one O
OH
 
11108 
4984-85-4 
Liquid 
C6H12O2 
116.16 
Sparingly 
soluble 
Freely 
soluble 
167 
 
MS 
95 % 
1.422-1.428 
0.949-0.955 
 
Racemate (EFFA, 2010). 
07.168 
 
2-Hydroxypiperitone 
OH
O
O
O
4143 
 
490-03-9 
Solid 
C10H16O2 
168.24 
Slightly 
soluble 
Freely 
soluble 
233 
82 
NMR MS 
98 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2010). 
07.184 
 
3-Methylnona-2,4-dione OO
 
4057 
 
113486-29-6 
Liquid 
C10H18O2 
170.25 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
52 (0.13 hPa) 
 
IR NMR MS 
97 % 
1.448-1.454 
0.923-0.927 
 
Racemate (EFFA, 2014). 
07.238 
 
3-Hydroxy-2-octanone O
OH
4139 
 
37160-77-3 
Liquid 
C8H16O2 
144.21 
Practically 
insoluble or 
insoluble 
Freely 
soluble 
91 (13 hPa) 
 
MS 
95 % 
1.431-1.437 
0.927-0.933 
 
Racemate (EFFA, 2010). 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 11, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility 
in ethanol 
(b) 
Boiling point, 
°C (c) 
Melting point, 
°C 
ID test 
Assay 
minimum 
Refrac. 
Index (d) 
Spec.gravity 
(e) 
Specification 
comments 
07.248 
 
Octan-2,3-dione O
O
4060 
 
585-25-1 
Liquid 
C8H14O2 
142.2 
Soluble 
Freely 
soluble 
58 (1.3 hPa) 
 
IR NMR MS 
95 % 
1.419-1.424 
0.905-0.913 
 
 
07.260 
 
1- or 3-Hydroxy-5-methyl-2- 
or 3-hexanone 
O
OH
3-Hydroxy-5-methyl-2-hexanone shown  
3989 
 
163038-04-8 
Liquid 
C7H14O2 
130.18 
Soluble 
Soluble 
171-173 
 
MS 
95 % 
0.921-0.933 
1.419-1.431 
 
Register name to be 
changed to 1-hydroxy-5-
methyl-3-hexanone and 
3-hydroxy-5-methyl-2-
hexanone. 75-77 % 3-
hydroxy-5-methyl-2-
hexanone and 20-22 % 2-
hydroxy-5-methyl-3-
hexanone. Mixture of 
diastereoisomers (25 % of 
each) (EFFA, 2014). 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
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2.3. Natural Occurrence in Food 
Nine of the 11 candidate substances have been reported to occur in fruits, fruit juice, vegetables, bread, 
cheese, fish, meat, peanuts, cocoa, wine, drinks, beer, tea, and coffee. Quantitative data on the natural 
occurrence in food have been reported for seven of these substances: 
Table 2:  Candidate Substances Reported to Occur in Food (EFFA, 2004b; Flavour Industry,   
2005b; TNO, 2000; TNO, 2014) 
FL-no: Name: Quantitative data reported 
02.133 Butane-2,3-diol 0.006 mg/kg in fish (lean), up to 90 mg/kg in cheddar 
cheese, up to 2.3 mg/kg in raspberry, up to 850 mg/kg in 
vinegar, up to 95 mg/kg in sherry and up to 2900 mg/kg in 
various types of wine 
07.152 3,3-Diethoxybutan-2-one Up to 0.1 mg/kg in cognac and weinbrand 
07.165 4-Hydroxy-4-methylpentan-2-one Up to 28.5 mg/kg in annatto, up to 0.07 mg/kg in roasted 
chicken, up to 2.7 mg/kg in honey, 0.41 mg/kg in passion 
fruit 
07.168 2-Hydroxypiperitone 36 mg/kg in black currant (buds) 
07.184 3-methyl-2,4-nonadione 0.083 mg/kg in tea 
07.238 3-Hydroxy-2-octanone Up to 15 mg/kg in lamb and mutton  
07.248 Octan-2,3-dione 0.1 mg/kg in fish (lean), up to 0.2 mg/kg in turkey (roasted), 
up to 0.07 mg/kg in chicken (roasted), up to 0.112 mg/kg in 
Guinea hen, up to 0.03 mg/kg in beef (grilled, roasted), up to 
108 mg/kg in lamb and mutton fat (heated), 0.01 mg/kg in 
peanuts 
 
According to TNO two of the substances have not been reported to occur naturally in any food items: 
Table 3:  Candidate Substances Not Reported to Occur in Food (TNO, 2000; TNO, 2014) 
FL-no: Name: 
07.097 3-(Hydroxymethyl)octan-2-one 
07.260 1- or 3-hydroxy-5-methyl-2- or 3-hexanone 
 
3. Specifications 
Purity criteria for the 11 candidate substances have been provided by the Flavour Industry (EFFA, 
2003a; EFFA, 2004b; EFFA, 2007b; EFFA, 2010; Flavour Industry, 2005a; Flavour Industry, 2005b) 
(see Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), the information is adequate for all candidate substances (see Section 2.2 and Table 1). 
4. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
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However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in 
the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability 
of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported). However, it is considered as a suitable tool to screen and prioritise the flavouring substances 
according to the need for refined intake data (EFSA, 2004). 
4.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry (IOFI), in which flavour 
manufacturers reported the total amount of each flavouring substance incorporated into food sold in 
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible 
natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population7 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
In the present Flavouring Group Evaluation 11, Revision 3 (FGE.11Rev3) the total annual volume of 
production of the 11 candidate substances for use as flavouring substances in Europe has been 
reported to be approximately 170 kg (EFFA, 2003b; EFFA, 2004b; EFFA, 2007b; Flavour Industry, 
2005a; Flavour Industry, 2005b). 120 kg is accounted for by 3-(hydroxymethyl)octan-2-one [FL-no: 
07.097], 25 kg is accounted for by butane-2,3-diol [FL-no: 02.133] and 19 kg is accounted for by 1- or 
3-hydroxy-5-methyl-2- or 3-hexanone [FL-no: 07.260]. For the 13 supporting substances the total 
annual volume of production has been reported by the JECFA to be approximately 38000 kg. Diacetyl 
[FL-no: 07.052] accounts for 18000 kg and 3-hydroxybutan-2-one [FL-no: 07.051] accounts for 19000 
kg (JECFA, 2000a). 
                                                     
7 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available 
for the enlarged EU. 
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On the basis of the annual volumes of production reported for the 11 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated (Table 5). The estimated daily per 
capita intake of 3-(hydroxymethyl)octan-2-one [FL-no: 07.097], butane-2,3-diol [FL-no: 02.133] and 
1- or 3-hydroxy-5-methyl-2 or 3-hexanone [FL-no: 07.260] from use as a flavouring substance is 15, 
3.0 µg and 2.3 µg, respectively. The daily per capita intakes for each of the remaining substances are 
equal to or less than 0.37 µg (Table 5). 
4.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of the modified Theoretical Added Maximum Daily Intake (mTAMDI) 
values is based on the approach used by SCF up to 1995 (SCF, 1995).  
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the 11 candidate substances, information on food categories and normal 
and maximum use levels8,9,10 were submitted by the Flavour Industry (EFFA, 2003a; EFFA, 2003b; 
EFFA, 2004b; EFFA, 2007a; EFFA, 2007b; Flavour Industry, 2005a; Flavour Industry, 2005b). 
The 11 candidate substances are used in flavoured food products divided into the food categories, 
outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000), as shown in 
Table 4. For the present calculation of mTAMDI, the reported normal use levels were used. In the case 
where different use levels were reported for different food categories the highest reported normal use 
level was used.  
Table 4:  Use of candidate substances 
Food category Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All  
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-no: 
07.260] 
03.0 Edible ices, including sherbet and sorbet All  
04.1 Processed fruits All 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, 
pulses and legumes), and nuts & seeds 
Only [FL-no: 
07.260] 
05.0 Confectionery All  
06.0 Cereals and cereal products, incl. flours & starches from roots & 
tubers, pulses & legumes, excluding bakery 
All except [FL-no: 
07.260] 
07.0 Bakery wares All 
08.0 Meat and meat products, including poultry and game All except [FL-no: 
07.260] 
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
All except [FL-no: 
07.260] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 
07.260] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 
07.260] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All  
                                                     
8 “Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002). 
9 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004a). 
10 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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Food category Description Flavourings used 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic 
counterparts 
All  
15.0 Ready-to-eat savouries All except [FL-no: 
07.260] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods 
that could not be placed in categories 1 – 15 
All except [FL-no: 
07.260] 
 
According to the Flavour Industry, the normal use levels for the candidate substances are in the range 
of 1 – 20 mg/kg food, and the maximum use levels are in the range of 3 – 100 mg/kg (EFFA, 2003a; 
EFFA, 2003b; EFFA, 2004b; EFFA, 2007b; Flavour Industry, 2005a; Flavour Industry, 2005b) (See 
Table B.1.2, Appendix B).  
The mTAMDI values for the five candidate substances from structural class I (see Section 7) range 
from 1600 to 3900 µg/person/day. For the six candidate substances from structural class II the 
mTAMDI values range from 1500 to 1600 µg/person/day. For the one candidate substance [FL-no: 
07.168] from structural class III the mTAMDI value is 1600 µg/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Appendix B. 
5. Absorption, Distribution, Metabolism and Elimination 
Ketals are expected to be readily hydrolysed after ingestion under the acidic conditions in the stomach 
to the corresponding alcohols and ketones.  
The candidate substances, which are α- and β-diketones, ketal, hydroxyketones or diols, are expected 
to be absorbed from the gastrointestinal tract. The metabolic fate of acyclic aliphatic diketones 
depends primarily on the position of the carbonyl function and the chain length. Aliphatic acyclic 
diketones and α-hydroxyketones which contain a carbonyl function at the 2-position (i.e. a methyl 
ketone) may undergo α–hydroxylation and subsequent oxidation of the terminal methyl group to 
eventually yield corresponding ketocarboxylic acids. The ketoacids are intermediary metabolites (e.g. 
α-ketoacids), which may undergo oxidative decarboxylation to yield carbon dioxide and an aliphatic 
carboxylic acid. The acid may be completely metabolised in the fatty acid pathway and citric acid 
cycle. β-Keto-acids and derivatives readily undergo decarboxylation. Along with α-keto- and α-
hydroxyacids, they yield breakdown products, which are incorporated into normal biochemical 
pathways. 
Alternatively, the methyl-substituted diketones may be successively reduced to the corresponding 
hydroxyketones and diols, which are excreted in the urine as glucuronic acid conjugates. This pathway 
is favoured at elevated in vivo concentrations, especially for longer chain length ketones. α-
Hydroxyketones or their diol metabolites may be excreted as glucuronic acid conjugates. If the 
carbonyl function is located elsewhere on the chain or in a ring, reduction is the predominant 
detoxification pathway. 
A more detailed discussion on the metabolism of these α-, β-diketones, a related ketal, hydroxyketones 
and diols follows in Appendix C. 
6. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
In FGE.11, one of the six candidate substances, pentan-2,4-dione, was, based on the genotoxicity data 
available, considered genotoxic in vitro and in vivo and accordingly, the Procedure was not applied for 
this substance. The candidate substance 3-methyl-2,4-nonadione [FL-no: 07.184] contains a structural 
2,4-dione element similar to pentan-2,4-dione. The genotoxicity data available for this substance are 
two valid un-published GLP studies in Salmonella typhimurium and Escherichia coli which were 
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negative, and a recent valid unpublished in vitro micronucleus assay, which was also negative. Based 
on the lack of genotoxicity at gene and chromosome levels, 3-methylnona-2,4-dione can be evaluated 
through the Procedure. The application of the Procedure is based on intakes estimated on the basis of 
the MSDI approach. Where the mTAMDI approach indicates that the intake of a flavouring substance 
might exceed its corresponding threshold of concern, a formal safety assessment, using the mTAMDI 
approach, is not carried out using the Procedure. In these cases the Panel requires more precise data on 
use and use levels. For comparison of the intake estimations based on the MSDI approach and the 
mTAMDI approach, see Section 7. 
For the safety evaluation of the 11 candidate substances from chemical groups 8 and 10 the Procedure 
was applied. The stepwise evaluations are summarised in Table 6. 
Step 1 
Five of the candidate substances [FL-no: 02.133, 07.097, 07.165, 07.167 and 07.238], are classified 
into structural class I according to the decision tree approach presented by Cramer et al. (Cramer et al., 
1978). Five of the candidate substances are classified in structural class II [FL-no: 07.071, 07.152, 
07.184, 07.248 and 07.260] and the remaining substance [FL-no: 07.168] is classified into structural 
class III.  
Step 2 
Ketals are expected to be readily hydrolysed after ingestion under the acid conditions in the stomach to 
the corresponding alcohols and ketones.  
At the estimated levels of intake, the candidate substances would not be expected to saturate metabolic 
detoxification pathways. They are considered to be metabolised to innocuous products. The evaluation 
of the 11 candidate substances, therefore, proceeds via the A-side of the Procedure scheme.  
Step A3 
The estimated levels of intake for the five candidate substances classified into structural class I are in 
the range of 0.0012 - 15 µg/capita/day, which are below the human intake threshold of concern for 
structural class I (1800 µg/person/day). The intakes of five class II candidate substances are 0.0012 – 
2.3 µg/capita/day, which also are below the human intake threshold for that class (540 µg/person/day). 
The intake of the one class III candidate substance [FL-no: 07.168] is 0.0012 µg/capita/day, which is 
below the human intake threshold for that class (90 µg/person/day) (Table 6).  
Based on the results of the safety evaluation sequence of the Procedure, these 11 candidate substances 
proceeding via the A-side of the Procedure scheme do not pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on MSDI approach. 
7. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for the five candidate substances in structural class I based on the mTAMDI 
approach range from 1600 to 3900 µg/person/day. For one of the substances the mTAMDI value is 
above the threshold of concern for structural class I of 1800 µg/person/day.  
The estimated intakes for the five candidate substances assigned to structural class II based on the 
mTAMDI range from 1500 to 1600 µg/person/day, which are above the threshold of concern for 
structural class II substances of 540 µg/person/day.  
The estimated intake for the one candidate substance 2-hydroxypiperitone [FL-no: 07.168] assigned to 
structural class III based on the mTAMDI is 1600 µg/person/day, which is above the threshold of 
concern for structural class III substances of 90 µg/person/day.  
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Thus, for seven candidate substances [FL-no: 02.133, 07.071, 07.152, 07.248, 07.260, 07.184 and 
07.168] further information is required. This would include more reliable intake data and then, if 
required, additional toxicological data. 
For comparison of the intake estimate based on the MSDI approach and the mTAMDI approach see 
Table 5. 
Table 5:  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
02.133 Butane-2,3-diol 3 3900 Class I 1800 
07.097 3-(Hydroxymethyl)octan-
2-one 
15 1600 Class I 1800 
07.165 4-Hydroxy-4-
methylpentan-2-one 
0.085 1600 Class I 1800 
07.167 4-Hydroxyhexan-3-one 0.0012 1600 Class I 1800 
07.238 3-Hydroxy-2-octanone 0.0049 1600 Class I 1800 
07.071 Octane-4,5-dione 0.0012 1600 Class II 540 
07.152 3,3-Diethoxybutan-2-one 0.088 1600 Class II 540 
07.184 3-Methylnona-2,4-dione 0.35 1600 Class II 540 
07.248 Octan-2,3-dione 0.37 1600 Class II 540 
07.260 1- or 3-Hydroxy-5-
methyl-2- or 3-hexanone 
2.3 1500 Class II 540 
07.168 2-Hydroxypiperitone 0.0012 1600 Class III 90 
8. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003a; EFFA, 2003b; 
EFFA, 2004b; EFFA, 2007b; Flavour Industry, 2005a; Flavour Industry, 2005b) the estimated 
combined daily per capita intake as flavourings of the 11 candidate substances assigned to structural 
class I, II or III is 21 µg, which do not exceed the thresholds of concern for substances belonging to 
structural class I of 1800 or II of 540 or III of 90 µg/person/day, respectively. 
The 11 candidate substances [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 07.184, 
07.238, 07.248 and 07.260] are structurally related to 13 supporting substances, which all are α-
diketones or precursors evaluated by the JEFCA at its 51st meeting. For 12 of these supporting 
substances European annual production volumes have been provided by Flavour Industry. The 12 
supporting substances are all assigned to structural class II. The total estimated combined daily intake 
of the candidate and supporting substances (in Europe) is approximately 4600 µg/capita, which would 
exceed the threshold of concern for structural class II (540 µg/person/day). 
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However, based on the high capacity of enzymes in the metabolic pathways, it is anticipated that the 
combined intake of candidate substances (21 µg/capita/day) and supporting substances (4600 
µg/capita/day) would be metabolised efficiently and would not saturate these metabolic pathways. 
Further, based on the data available, two supporting substances (diacetyl [FL-no: 07.052] 2200 
µg/capita/day and 3-hydroxybutan-2-one [FL-no: 07.051] 2300 µg/capita/day) out of the total of 23 
candidate and supporting substances provide 95 % of the contribution. These are present in the body 
as endogenous compounds (Kawano, 1959; Gabriel et al., 1972) and they would not be expected to 
give rise to perturbations outside the physiological range (JECFA, 1999a). Therefore, at the level of 
exposure, based on the MSDI approach, the total combined intake as flavouring substances of the 
candidate and supporting substances would not be expected to be of safety concern. 
9. Toxicity 
9.1. Acute Toxicity 
Data are available for three candidate substances ([FL-no: 02.133, 07.165 and 07.184]) and for pentan-
2,4-dione and for six of the supporting substances [FL-no: 07.018, 07.051, 07.052, 07.060, 07.064 and 
09.264] evaluated by JECFA (JECFA, 1999a).  
Oral LD50 values in rats and mice are in the range from 600 to 9000 mg/kg body weight (bw). 
The acute toxicity data are summarised in Table 9.  
9.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data on oral subacute toxicity are available for one candidate substance ([FL-no: 07.165]), for the 
structurally related pentan-2,4-dione and for three supporting substances [FL-no: 07.051, 07.052, and 
07.077] evaluated by the JECFA (JECFA, 1999a). There are no studies available on chronic toxicity 
and carcinogenicity for the candidate substances. No Observed Adverse Effect Levels (NOAELs) in 
the range of 10 - 100 mg/kg bw/day in rats (and rabbits) have been derived from subacute studies for 
one candidate substance [FL-no: 07.165] and for pentan-2,4-dione and in the range of 90 - 330 mg/kg 
bw/day from subchronic studies in rats for two supporting substances [FL-no: 07.051 and 07.052]. 
Repeated dose toxicity data are summarised in Table 10. 
9.3. Developmental / Reproductive Toxicity Studies 
There are no data available for candidate substances. For supporting substances there is one 
developmental toxicity study available for diacetyl [FL-no: 07.052] in which no adverse effects were 
observed at the applied dose levels up to 1600 mg/kg bw/day in hamsters, mice and rats. 
The developmental/reproductive toxicity study is summarised in Table 11. 
9.4. Genotoxicity Studies 
In vitro data are available for three candidate substances [FL-no: 02.133, 07.165 and 07.184], diacetyl-
trimer former candidate substance [FL-no: 06.134], for the structurally related pentan-2,4-dione and 
for five supporting substances [FL-no: 07.051, 07.052, 07.060, 07.018 and 07.077].  
For one of the candidate substances 4-hydroxy-4-methylpentan-2-one [FL-no: 07.165], in vitro studies 
have been reported with negative results obtained in bacterial gene mutation assays with and without 
metabolic activation as well as in a chromosomal aberration assay in rat liver cells in vitro. For a 
second candidate substance butane-2,3-diol [FL-no: 02.133], there is only one Ames test reported to 
be negative, but the validity of the study cannot be evaluated. No evidence of mutagenicity was 
reported in standard or modified Ames assays considered valid when 3-methyl-2,4-nonanedione [FL-
no: 07.184] and diacetyl-trimer, a former candidate substance ([FL-no: 06.134]) were incubated with 
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various strains of S. typhimurium or E. coli at concentrations up to 5000 μg/plate, with and without 
metabolic activation (Stien, 2005; Sasaki, 2006). 
For pentan-2,4-dione, both in vitro and in vivo studies are available. In the various in vitro studies 
reported (reverse mutation assays (Ames Tests), microbial DNA repair tests and tests on primary DNA 
damage, gene mutation and chromosomal aberrations) negative results were observed in one Ames 
Test with five tester strains of S. typhimurium with and without metabolic activation. Positive results 
were found in two Ames Tests with S. typhimurium strain TA104 with or without metabolic 
activation. Positive results were also observed in the chromosomal aberrations test in the absence of 
metabolic activation. For the three tests on microbial DNA repair both positive and negative results 
have been reported. However, they followed unusual study protocols and experimental details are 
insufficiently reported. Thus, the results are of limited validity. In two in vivo micronucleus studies 
using intraperitoneal dosing, which were performed in compliance with GLP and in accordance with 
OECD Guideline 474 in mice significant increases in micronucleated polychromatic erythrocytes were 
observed in peripheral blood as well as in bone marrow. Test concentrations used were high and close 
to the LD50 determined in the same test system, however, there was no decrease in the ratio of 
PCE/NCE, on the contrary an increase was reported. The results were clearly positive in both studies 
which are considered as valid. The same test protocol was used in an in vivo micronucleus study in 
rats. However, test concentrations had to be reduced due to excessive mortality. Under these 
conditions, negative results were observed in the micronucleus test in rats. There were no significant 
changes in the proportion of PCE. Therefore, the validity of the results of this study is limited.  
3-Methylnona-2,4-dione [FL-no: 07.184] was tested in an in vitro micronucleus assay (Watters, 2013) 
using duplicate human lymphocyte cultures prepared from the pooled blood of two female donors in a 
single experiment. It is a valid GLP study carried out in compliance with OECD Guideline 487. 
Treatments covering ranges of concentrations from 80 – 815 μg/mL, depending on the tested 
conditions, separated by narrow intervals, were performed both in the absence and presence of 
metabolic activation (S-9) from Aroclor 1254-induced rats. The test article was formulated in 
anhydrous analytical grade dimethyl sulphoxide (DMSO) and the highest concentrations tested in the 
micronucleus experiment (limited by toxicity) were determined following a preliminary cytotoxicity 
range-finder experiment.  
Treatments were conducted 48 hours following mitogen stimulation by phytohaemagglutinin (PHA). 
The test article concentrations for micronucleus analysis were selected by evaluating the effect of 3-
methylnona-2,4-dione on the replication index (RI).  
Appropriate positive and negative (vehicle) control cultures were included in the test system under 
each treatment condition. The proportion of micronucleated binucleate (MNBN) cells in the vehicle 
cultures fell within the 95th percentile of the current observed historical vehicle control (normal) 
ranges.  
Treatment of cells with 3-methylnona-2,4-dione in the absence and presence of S-9 resulted in 
frequencies of MNBN cells that were generally similar to those observed in concurrent vehicle 
controls for all concentrations analysed under all three treatment conditions. 
The MNBN cell frequency of all but a single treated culture fell within the normal ranges. This 
isolated increase in MNBN cell frequency occurred at an intermediate concentration (400 µg/mL) 
following 3+21 hour treatment in the absence of S-9. As this small increase was not reproduced in the 
replicate culture or any other culture analysed and the mean MNBN cell frequencies of all 
concentrations analysed fell within the normal range, it was considered of no biological relevance. 
It is concluded that 3-methylnona-2,4-dione did not induce micronuclei in cultured human peripheral 
blood lymphocytes following treatment in the absence and presence of a rat liver metabolic activation 
system (S-9), when tested up to cytotoxic concentrations. 
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Genotoxicity studies were also performed with five supporting substances: 
For 3-hydroxybutan-2-one (acetoin) [FL-no: 07.051] there is only one valid negative Ames test while 
data from other in vitro studies (results of which were reported to be negative) cannot be considered as 
valid. Diacetyl [FL-no: 07.052] was found able to induce gene mutations in S. typhimurium TA100 
and TA104. Diacetyl was reported to produce mutations in the TK +/- locus of L5178Y mouse 
lymphoma cells. However, the concentration required for a two-fold increase in mutations results in a 
62 % growth reduction, rendering this effect questionable (Whittaker et al., 2008). In an unpublished 
GLP study on in vivo micronucleus formation in B6C3F1 mice diacetyl was reported negative, 
however, since the PCE/NCE ratio was not reported it is not clear whether the test substance reached 
the target organ (NTP, 1994). Hexan-3,4-dione [FL-no: 07.077] slightly induced gene mutations in 
bacteria. No genotoxic activity was observed in valid in vitro studies with pentan-2,3-dione [FL-no: 
07.060] and hexan-2,3-dione [FL-no: 07.018] (see Table 12.). 
Conclusion on genotoxicity:  
There are mutagenicity data on four candidate substances ([FL-no: 02.133, 06.134, 07.165 and 
07.184]) and for the structurally related pentan-2,4-dione in this flavouring group evaluation. 
4-Hydroxy-4-methylpentan-2-one [FL-no: 07.165] was not mutagenic in various in vitro studies in 
bacteria and yeast and did not induce chromosomal aberrations in rat liver cells. For butane-2,3-diol 
[FL-no: 02.133] negative results were reported in an in vitro gene mutation study, of which, however, 
the validity cannot be evaluated. No evidence of mutagenicity was reported in Ames assays considered 
valid when 3-methyl-2,4-nonanedione [FL-no: 07.184] and diacetyl-trimer, a former candidate 
substance ([FL-no: 06.134]) were incubated with various strains of S. typhimurium or E. coli. 
Furthermore, the results of a valid in vitro micronucleus assay indicate that 3-methyl-2,4-nonanedione 
[FL-no: 07.184] does not induce chromosomal damage with and without metabolic activation. 
Mutagenicity data are available for five of the 13 supporting substances, giving mainly negative 
results. There is indication that diacetyl [FL-no: 07.052] has a weak genotoxic activity in vitro. 
However, diacetyl is reported to be endogenous in humans and is reported to be rapidly reduced to 
acetoin and further to butan-2,3-diol, for which there are no indication of mutagenicity. 
Overall, the genotoxicity data available on candidate and supporting substances do not preclude 
evaluation of the candidate substances in the present group using the Procedure. Data on genotoxicity 
are summarised in Table 12 and 13. 
CONCLUSIONS 
The present flavouring group includes 11 candidate substances; eight α-diketones or their 
corresponding alcohols or ketals [FL-no: 02.133, 07.071, 07.152, 07.167, 07.168, 07.238, 07.248 and 
07.260], and three β-diketones or their corresponding β-hydroxyketones (of which one is a tertiary 
alcohol) [FL-no: 07.165, 07.097 and 07.184] all belonging to chemical groups 8 and 10. 
The present Revision of FGE.11, FGE.11Rev3 is prepared due to the evaluation of genotoxicity data, 
which have been requested in the previous version of FGE.11, for 3-methylnona-2,4-dione [FL-no: 
07.184]. Additionally, new information on natural occurrence in food [FL no: 07.165, 07, 184 and 
07.238] and on the stereoisomerism for [FL-no: 07.184 and 07.260] and composition for one 
substance [FL-no: 07.097] has become available. 
Two of the candidate substances possesses two chiral centres [FL-no: 02.133 and 07.168] and five 
substances possesses one chiral centre [FL-no: 07.097, 07.167, 07.184, 07.238 and 07.260]. For all 
substances, the stereoisomeric composition has been specified sufficiently. 
Five of the candidate substances are classified in structural class I, and five are classified in structural 
class II and one is classified in structural class III.  
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Nine of the candidate substances in the present group have been reported to occur naturally in a wide 
range of food items. 
According to the default MSDI approach, the candidate substances, assigned to structural class I, II or 
III, have European daily per capita intakes ranging from 0.0012 to 15 µg, which are below the 
thresholds of concern for their respective structural class of 1800, 540 and 90 µg/person/day. 
The total combined MSDI of candidate and supporting substances (all from structural class II) is 
approximately 4600 µg/capita, which exceeds the threshold of concern for structural class II (540 
µg/person/day). However, based on information on efficient metabolism and on presence in the body 
as endogenous compounds, there are no safety concerns from the combined intakes of the candidate 
and supporting substances. 
Data available for the candidate substance, 3-methyl-2,4-nonadione [FL-no: 07.184], shows that this 
substance has no genotoxic potential in vitro. For the remaining candidate substances in the present 
group genotoxicity data are only available for a limited number and the genotoxicity could not be 
assessed adequately. However, the genotoxicity data available do not preclude evaluation using the 
Procedure. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that on the basis of the default MSDI approach the 11 candidate substances evaluated 
through the Procedure [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 07.184, 
07.238, 07.248 and 07.260] would not give rise to safety concerns at the estimated levels of intake 
arising from their use as flavouring substances. 
When the estimated intakes were based on the mTAMDI they ranged from 1600 to 3900 
µg/person/day for the five candidate substances from structural class I. For one of these candidate 
substances [FL-no: 02.133] the estimated intake is above the threshold of concern of 1800 
µg/person/day for structural class I. For the five candidate substances which are allocated to structural 
class II, the estimated intake based on the mTAMDI range from 1500 to 1600 µg/ person/day, which is 
above the threshold of concern for structural class II of 540 µg/person/day. For the one candidate 
substance [FL-no: 07.168] from structural class III the mTAMDI value is 1600 µg/person/day, which 
exceeds the threshold of concern for structural class III of 90 µg/person/day.  
Thus, for seven of the 11 candidate substances evaluated through the Procedure [FL-no: 02.133, 
07.071, 07.152, 07.168, 07.184, 07.248 and 07.260] the intakes, estimated on the basis of the 
mTAMDI exceed the threshold for the structural class, to which the flavouring substances have been 
assigned. Therefore, more reliable exposure data are required. On the basis of such additional data, the 
substances should be reconsidered along the steps of the Procedure. Following this procedure 
additional toxicological data might become necessary. The four candidate substances [FL-no: 07.097, 
07.165, 07.167 and 07.238], which have mTAMDI intake estimates below the threshold of concern for 
structural class I are also expected to be metabolised to innocuous products. 
In order to determine whether the conclusion for the candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specification 
and data on stereoisomerism are available for all the candidate substances.  
Thus, all 11 substances [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 07.184, 
07.238, 07.248 and 07.260] evaluated in the present FGE would not present any safety concern at the 
estimated levels of intake based on the MSDI approach. 
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SUMMARY OF SAFETY EVALUATION 
Table 6:  Summary of Safety Evaluation Applying the Procedure 
FL-no EU Register name Structural formula MSDI (a) 
(μg/capita/day) 
Class (b) 
Evaluation 
procedure path (c) 
Outcome on the 
named 
compound [(d) 
or (e)] 
Outcome on 
the material of 
commerce [(f) , 
(g) or (h)] 
Evaluation remarks 
02.133 
 
Butane-2,3-diol 
OH
OH 3 
 
Class I 
A3: Intake below 
threshold 
d f  
07.097 
 
3-
(Hydroxymethyl)octan-
2-one 
OH
O 15 
 
Class I 
A3: Intake below 
threshold 
d f  
07.165 
 
4-Hydroxy-4-
methylpentan-2-one 
O
OH
0.085 
 
Class I 
A3: Intake below 
threshold 
d f  
07.167 
 
4-Hydroxyhexan-3-one O
OH
0.0012 
 
Class I 
A3: Intake below 
threshold 
d f  
07.238 
 
3-Hydroxy-2-octanone O
OH
0.0049 
 
Class I 
A3: Intake below 
threshold 
d f  
07.071 
 
Octane-4,5-dione 
O
O 0.0012 
 
Class II 
A3: Intake below 
threshold 
d f  
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Table 6:  Summary of Safety Evaluation Applying the Procedure 
FL-no EU Register name Structural formula MSDI (a) 
(μg/capita/day) 
Class (b) 
Evaluation 
procedure path (c) 
Outcome on the 
named 
compound [(d) 
or (e)] 
Outcome on 
the material of 
commerce [(f) , 
(g) or (h)] 
Evaluation remarks 
07.152 
 
3,3-Diethoxybutan-2-
one O
O
O
0.088 
 
Class II 
A3: Intake below 
threshold 
d f  
07.184 
 
3-Methylnona-2,4-dione OO 0.35 
 
Class II 
A3: Intake below 
threshold 
d f  
07.248 
 
Octan-2,3-dione O
O
0.37 
 
Class II 
A3: Intake below 
threshold 
d f  
07.260 
 
1- or 3-Hydroxy-5-
methyl-2- or 3-
hexanone 
O
OH
3-Hydroxy-5-methyl-2-hexanone shown
2.3 
 
Class II 
A3: Intake below 
threshold 
d f  
06.134 
 
Diacetyl-trimer O
O
O
O
HO
O 1.2 
 
Class II 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 No longer supported by 
Industry, (DG SANCO, 
2012). 
07.168 
 
2-Hydroxypiperitone 
OH
O
O
O
0.0012 
 
Class III 
A3: Intake below 
threshold 
d f  
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
(b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
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(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE KETAL 
Table 7:  Evaluation Status of Hydrolysis Products of Candidate Ketal 
FL-no EU Register name 
JECFA no 
Structural formula SCF status (a) 
JECFA status (b) 
CoE status (c) 
EFSA status 
Structural class (d) 
Procedure path (JECFA) (e) 
Comments 
 3-Hydroxy-3-methyl-
hept-2,5,6-trione 
O
O
O
OH  
Not in register Not in register Anticipated  hydrolysis 
products of diacetyl-
trimer, a former 
candidate substance 
[FL-no: 06.134]. 
02.078 Ethanol 
41 
OH  Category 1 (SCF, 1995) 
No safety concern (JECFA, 1997) 
 
 
 
No evaluation 
At the forty-sixth 
JECFA meeting 
(JECFA, 1997), the 
Committee concluded 
that ethanol posed no 
safety concern at its 
current level of intake 
when ethyl esters are 
used as flavouring 
agents. 
07.052 Diacetyl 
408 
O
O
 
No safety concern (JECFA, 2000a) 
Category A (CoE, 1992) 
 
Class II 
A3: Intake above threshold, A4: 
Endogenous 
 
(a): Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4: Not acceptable due to 
evidence of toxicity. 
(b): No safety concern at estimated levels of intake. 
(c): Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
(d): Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(e): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
 
Flavouring Group Evaluation 11 Revision 3
 
EFSA Journal 2014;12(11):3888 25
SUPPORTING SUBSTANCES SUMMARY 
Table 8:  Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) (a) 
(μg/capita/day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
07.018 Hexan-2,3-dione 
O
O
 
2558 
152 
3848-24-6 
412 
JECFA 
specification 
(JECFA, 2000b) 
8.5  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
 
07.021 Undeca-2,3-dione 
O
O 3090 
155 
7493-59-6 
417 
JECFA 
specification 
(JECFA, 2003) 
0.0037  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
 
07.051 3-Hydroxybutan-2-one O
OH  
2008 
749 
513-86-0 
405 
JECFA 
specification 
(JECFA, 1998) 
2300  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
JECFA evaluated 
acetoin (CASrn as 
in Register). (R)- 
or (S)-enantiomer 
not specified by 
CASrn in 
Register. 
07.052 Diacetyl O
O  
2370 
752 
431-03-8 
408 
JECFA 
specification 
(JECFA, 1998) 
2200  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
 
07.060 Pentan-2,3-dione O
O  
2841 
2039 
600-14-6 
410 
JECFA 
specification 
(JECFA, 2003) 
130  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
 
07.063 4-Methylpentan-2,3-dione O
O  
2730 
2043 
7493-58-5 
411 
JECFA 
specification 
(JECFA, 2000b) 
0.3  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
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Table 8:  Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) (a) 
(μg/capita/day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
07.064 Heptan-2,3-dione O
O  
2543 
2044 
96-04-8 
415 
JECFA 
specification 
(JECFA, 1998) 
0.97  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
 
07.065 5-Hydroxyoctan-4-one 
O
OH
 
2587 
2045 
496-77-5 
416 
JECFA 
specification 
(JECFA, 2001) 
0.012  
No safety concern 
(JECFA, 2000a) 
Deleted  (CoE, 
1992) 
JECFA evaluated 
5-hydroxy-4-
octanone (CASrn 
as in Register). 
CASrn in Register 
refers to the 
racemate. 
07.077 Hexan-3,4-dione 
O
O
 
3168 
2255 
4437-51-8 
413 
JECFA 
specification 
(JECFA, 1998) 
21  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
 
07.093 5-Methylhexan-2,3-dione O
O
3190 
11148 
13706-86-0 
414 
JECFA 
specification 
(JECFA, 2000b) 
1.1  
No safety concern 
(JECFA, 2000a) 
 
 
07.125 3-Hydroxypentan-2-one O
OH  
3550 
11115 
3142-66-3 
409 
JECFA 
specification 
(JECFA, 2003) 
ND  
No safety concern 
(JECFA, 2000a) 
 
JECFA evaluated 
3-hydroxy-2-
pentanone 
(CASrn as in 
Register). (R)- or 
(S)-enantiomer 
not specified by 
CASrn in 
Register. 
09.186 sec-Butan-3-onyl acetate 
O
O
O
 
3526 
608 
4906-24-5 
406 
JECFA 
specification 
(JECFA, 2000b) 
0.024  
No safety concern 
(JECFA, 2000a) 
Category A (CoE, 
1992) 
JECFA evaluated 
2-acetoxy-3-
butanone (CASrn 
as in Register). 
(R)- or (S)-
enantiomer not 
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Table 8:  Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) (a) 
(μg/capita/day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
Comments 
specified by 
CASrn in 
Register. 
09.264 sec-Butan-3-onyl butyrate 
O
O
O  
3332 
10525 
84642-61-5 
407 
JECFA 
specification 
(JECFA, 2000b) 
0.012  
No safety concern 
(JECFA, 2000a) 
 
JECFA evaluated 
butan-3-one-2-yl 
butanoate (CASrn 
as in Register). 
(R)- or (S)-
enantiomer not 
specified by 
CASrn in 
Register. 
(a): EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
(b): Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to 
evidence of toxicity. 
(c): No safety concern at estimated levels of intake. 
(d): Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
 
Flavouring Group Evaluation 11 Revision 3
 
EFSA Journal 2014;12(11):3888 28
TOXICITY DATA 
Table 9:  Acute Toxicity 
Chemical Name [FL-no](a) Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Acetoin [07.051]) Rat  NR  Oral  >5000  (Moreno, 1977)  
Butane-2,3-diol [02.133]  Mouse  NR  Oral  9000  (Kopf et al., 1950)  
(Butan-3-one-2-yl butanoate [09.264]) Mouse  NR  Oral  >8000  (Pellmont, 1969)  
 Rat  NR  Oral  >8000  (Pellmont, 1969)   
(Diacetyl [07.052]) Rat  M, F  Gavage  M: 3400;  
F: 3000 
(Colley et al., 1969)  
 Rat  NR  Gavage  1580  (Jenner et al., 1964)  
 Guinea pig NR  Gavage  990  (Jenner et al., 1964)   
4-Hydroxy-4-methylpentan-2-one [07.165] Rat  M  Gavage  4920 (Myers et al., 1977)  
 Rat  M  Oral  4000 (Smyth, 1946a)  
(2,3-Pentanedione [07.060]) Rat  NR  Oral  3000  (Moreno, 1977)  
[Pentan-2,4-dione] Rat  M  Oral  1000 (Smyth, 1941)  
 Rat  M, F  Gavage  M: 780; 
F: 590  
(Ballantyne et al., 1986) 
(Myers et al., 1985)  
 
 Rat  M  Oral  800  (Eastman Kodak Co., 1992)  
 Mouse  M  Oral  951  (Eastman Kodak Co., 1992)  
(2,3-Hexanedione [07.018]) Rat  NR  Oral  >5000  (Moreno, 1977)  
(2,3-Heptanedione [07.064]) Rat NR Oral >5000 (Moreno, 1979)  
1- or 3-Hydroxy-5-methyl-2- or 3-
hexanone [07.260] 
Rat M, F Gavage >2000 (Strobel, 1998)  
NR: Not reported 
M= Male; F= Female 
(a): Supporting substances are listed in brackets. 
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Table 10:  Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name  
[FL-no]* 
Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg/day) 
Reference Comments 
(Acetoin [07.051])  Rat; M, F 
30 
Drinking 
water 
0, 85, 330, 1345 mg/kg 
bw/d 
90 Days  330  (Gaunt et al., 1972) Non-GLP study of good quality 
carried out as part of the BIBRA 
safety evaluation programme; 
published in a peer reviewed journal. 
(Diacetyl [07.052])  Rat; M, F 
30 
Gavage  0, 10, 30, 90, 540 mg/kg 
bw/d 
90 Days  90  (Colley et al., 1969) Non-GLP study of good quality 
carried out as part of the BIBRA 
safety evaluation programme; 
published in a peer reviewed journal. 
4-Hydroxy-4-
methylpentan-2-one 
[07.165] 
Rat;  NR 
10 
Drinking 
water 
0, 10, 40, 130 mg/kg bw/d 30 Days  10  (Smyth, 1946b) Unpublished non-GLP study of poor 
quality with respect to study protocol. 
No histopathological examination of 
high dose and control group. No 
details available for method and 
results. 
[Pentan-2,4-dione] Rat; M  
5 
Gavage  0, 100, 500, 1000 mg/kg 
bw/d 
1-15 Days(a)  100  (Eastman Kodak Co., 1992) Non-GLP study of 1979 in 
unpublished summary report. No 
details available for method and 
results. Quality of study limited with 
respect to study design. Results of the 
study have been published in 
Neurotoxicity of Industrial and 
Commercial Chemicals, Vol. 2, I.L. 
O’Donoghue, Editor, CRC Press, 
Boca Raton, Florida. p.77 (1985). 
 Rat; M  
5 
Gavage  0, 100 mg/kg bw/d 14 Days(b)  100(c)  (Eastman Kodak Co., 1992) 
 Rat; M  
5 
Gavage  0, 200 to 500 mg/kg bw/d 126 Days(d)  <200(e)  (Eastman Kodak Co., 1992) 
 Rabbit; M 
2 
Gavage  0, 250, 500, 1000 mg/kg 
bw/d 
14 Days(b)  250(f)  (Eastman Kodak Co., 1992) 
(3,4-Hexanedione 
[07.077]) 
Rat; M, F 
10-16 
Diet  0, 17 mg/kg bw/d 90 Days  17(c)  (Posternak et al., 1969) Summary of an unpublished non-GLP 
study (on 42 flavouring substances 
carried out in 1962-1967) prepared by 
BIBRA and published in a peer-
reviewed journal. 
NR= not reported.  
M = Male; F = Female  
*: Supporting substances are listed in brackets. 
(a): Animals dosed daily, between 1 and 11 times.  
(b): Animals dosed ten times in fourteen days.  
(c): The study was performed at a single dose level or multiple dose levels that produced no adverse effects. 
(d): Animals dosed twice per day over a 126 day period at doses ranging from 100 to 250 mg/kg/day; animals that died or were killed during the study due to poor condition were replaced.  
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(e): NOAEL for the central nervous system was determined to be <200 mg/kg/day.  The NOAEL for thymus toxicity was determined to be 200 mg/kg/day.  
(f): One rabbit (50 % of the group population) died due to possible aspiration of the test substance.  
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Table 11:  Developmental and reproductive toxicity studies 
Chemical Name  
[FL-no]* 
Study type 
Duration 
Species/Sex 
No/Group 
Route Dose levels 
mg/kg bw/day 
NOAEL 
(mg/kg/day), 
Including 
information of 
possible maternel 
toxicity 
Reference Comments 
(Diacetyl [07.052]) Developmental 
toxicity: Gestation 
days 6-10 
Hamster; F 
21-25 
Gavage  0, 16, 74.3, 345, 1600 
mg/kg bw/d 
1600 (maternal)(a,b)
1600 (foetal)(b,c) 
(FDA, 1973) Unpublished non-GLP study of 
limited quality with respect to 
possible developmental effects. 
Developmental 
toxicity: Gestation 
days 6-15 
Mouse; F 
21-24 
Gavage  0, 16, 74.3, 345, 1600 
mg/kg bw/d 
1600 (maternal)(a,c)
1600 (foetal)(b,c) 
(FDA, 1973) Unpublished non-GLP study of 
limited quality with respect to 
possible developmental effects. 
Developmental 
toxicity: Gestation 
days 6-15 
Rat; F 
21-23  
Gavage  0, 16, 74.3, 345, 1600 
mg/kg bw/d 
1600 (maternal)(a,c)
1600 (foetal)(b,c) 
(FDA, 1973) Unpublished non-GLP study of 
limited quality with respect to 
possible developmental effects. 
M = Male; F = Female.  
*  Supporting substances are listed in brackets. 
(a): Based on observations of maternal survival, body weight and reproductive parameters.  
(b): Based on observations of foetal survival and microscopic examination of foetal external, skeletal and soft tissues.  
(c): The study was performed at a single dose level or multiple dose levels that produced no adverse effects and, therefore, a NOAEL was not determined. The NOAEL is probably higher than 
the reported dose level that produced no adverse effects. 
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GENOTOXICITY DATA 
Table 12:  Genotoxicity (in vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
(Acetoin [07.051]) Ames Test  S. typhimurium TA100 up to 4500 µg/plate  Negative1  (Garst et al., 1983) Non-GLP study. Outcome of the 
study is only summarised with 
limited experimental details and 
no test results reported. Validity of 
the study cannot be evaluated. 
Ames Test  S. typhimurium TA100 390 µg/plate  Negative2  (Kim et al.,, 9987) Non-GLP study with limited 
information given on study 
protocol and results. Validity of 
the study cannot be evaluated. 
Ames Test  S. typhimurium TA98, TA100, 
TA102 
0.44 – 44000 µg/plate Negative3  (Aeschbacher et 
al., 1989) 
Good quality, non-GLP study. 
Ames Test  S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538; E. 
coli WP2 uvrA 
1 – 5000 µg/plate Negative2 (Iwata et al., 1984) Published study in Japanese. 
Results (i.e. average number of 
revertant colonies per plate from 
three plates for each test 
concentration, including positive 
and negative controls) are given in 
table. Only tested without 
metabolic activation. Validity of 
the study cannot be evaluated. 
Butane-2,3-diol [02.133] Ames Test  S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538; E. 
coli WP2 uvrA 
1 – 5000 µg/plate Negative2  (Iwata et al., 1984) Published study in Japanese. 
Results (i.e. average number of 
revertant colonies per plate from 
three plates for each test 
concentration, including positive 
and negative controls) are given in 
table. Only tested without 
metabolic activation. Validity of 
the study cannot be evaluated. 
(Diacetyl [07.052]) Ames Test  S. typhimurium TA100 90 µg/plate  Negative3 (Kim et al.,, 9987) Non-GLP study with limited 
information given on study 
protocol and results. Validity of 
the study cannot be evaluated. 
Modified Ames Test S. typhimurium TA98, TA100, 
TA104;  
NR  Positive1 (Kato et al., 1989) Only poorly reported abstract. 
Validity of the study cannot be 
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Table 12:  Genotoxicity (in vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
E. coli WP2 uvrA/pKM101 evaluated.  
Modified Ames Test S. typhimurium TA104 530 µg/plate   Positive   (Marnett et al., 
1985) 
Published non-GLP study 
assessing the sensitivity of the 
new base substitution strains 
TA102 and TA104 to the 
mutagenic effects of carbonyls. 
Metabolic activation not reported. 
Due to the limited details reported 
on experimental design and results 
the validity of the study cannot be 
evaluated 
Ames Test  S. typhimurium TA104 5 – 500 µg/plate4 Positive1 
Negative2 
(Shane et al., 
1988) 
Poorly reported non-GLP study of 
limited validity. Results are 
difficult to interpretate. 
Ames Test  S. typhimurium TA100, TA102 5 – 500 µg/plate4 Negative3  (Shane et al., 
1988) 
Poorly reported non-GLP study of 
limited validity. Results are 
difficult to interpretate. 
Ames Test  S. typhimurium TA100 152 – 950 µg/plate Positive2  (Dorado et al., 
1992) 
Published non-GLP study of good 
quality. The number of revertants 
at the highest dose duplicated that 
of spontanous revertants. The 
effect was dose-related. 
Ames Test  S. typhimurium TA100 Approx. 400-600 
µg/plate 
Positive3  (Bjeldanes and 
Chew, 1979) 
Published non-GLP study. Due to 
the limited details reported on 
experimental design and results 
the validity of the study cannot be 
evaluated. 
Ames Test  S. typhimurium TA98 10 – 10000 µg/plate Negative  (Bjeldanes and 
Chew, 1979) 
Published non-GLP study. Due to 
the limited details reported on 
experimental design and results 
the validity of the study cannot be 
evaluated. 
Ames Test  S. typhimurium TA102 0.17 – 17200 µg/plate Positive3,  (Aeschbacher et 
al., 1989) 
Good quality, non-GLP study. The 
number of revertants at the highest 
dose duplicated that of spontanous 
revertants. 
Ames Test  S. typhimurium TA98, TA100 0.17 – 17200 µg/plate Negative3 (Aeschbacher et Good quality, non-GLP study. 
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Table 12:  Genotoxicity (in vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
al., 1989) 
Modified Ames Test S. typhimurium TA100 1.8 and 4 mM4 (107 
and 238 μg/pl)  
Positive2  (Suwa et al., 1982) Published non-GLP study with 
limited details reported on 
experimental design and results. 
The validity of the study is 
considered limited. 
Ames Test  S. typhimurium TA98, TA100, 
TA1535, TA1537,TA 1538; E. 
coli WP2 uvrA  
1 – 5000 µg/plate Negative2  (Iwata et al., 1984) Published study in Japanese. 
Results (i.e. average number of 
revertant colonies per plate from 
three plates for each test 
concentration, including positive 
and negative controls) are given in 
table. Only tested without 
metabolic activation. Validity of 
the study cannot be evaluated. 
Ames Suspension Test S. typhimurium TA1535, 
TA1537, TA1538 
1 %  Negative3  (FDA, 1974) (not evaluated). 
Mutation  S. cerevisiae  NR  Negative3  (FDA, 1974) (not evaluated). 
Chromosomal 
Malsegregation Assay5 
S. cerevisiae D61.M 148 – 393 µg/ml Negative  (Zimmermann and 
Mohr, 1992) 
Published non-GLP study. Study 
is considered valid. 
Forward Mutation  Mouse lymphoma L5178Y 
TK+/- cells  
100 – 250 µg/ml  Positive (Whittaker et al., 
2008) 
Published non-GLP study. The 
result was positive. However, the 
concentration required for a two-
fold increase in mutations result in 
a 62 % growth reduction, 
rendering this effect questionable.  
4-Hydroxy-4-methylpentan-
2-one [07.165] 
Ames Test  S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538; 
100 – 10000 µg/plate Negative3  (San and Klug, 
1993) 
Plate incorporation assay. Non-
published GLP-study. 
Ames Test  S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538; E. 
coli  WP2, WP2 uvrA 
Up to 4000 µg/plate Negative3  (Brooks et al., 
1988) 
Plate incorporation assay. 
Published study summarising an 
extended industry report. Study is 
considered valid. 
Mitotic Gene 
Conversion Assay 
S. cerevisiae  10-5000 µg/ml  Negative3  (Brooks et al., 
1988) 
Published study summarising an 
extended industry report. Study is 
considered valid. 
Chromosome 
Aberrations 
Rat liver epithelial type- cell 
line RL4 
750, 1500, 2000, 3000, 
4000 µg/ml  
Negative  (Brooks et al., 
1988) 
Published study summarising an 
extended industry report. Study is 
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Table 12:  Genotoxicity (in vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
considered valid. 
(2,3-Pentanedione [07.060]) Ames Test  S. typhimurium TA100 105 µg/plate  Negative2  (Kim et al.,, 9987) Non-GLP study with limited 
information given on study 
protocol and results. Validity of 
the study cannot be evaluated. 
Ames Test  S. typhimurium TA98, TA100, 
TA102 
0.9 – 90000 µg/plate Negative3 (Aeschbacher et 
al., 1989) 
Good quality, non-GLP study 
[Pentan-2,4-dione] Ames Test  S. typhimurium TA98, TA100, 
TA1535, 1537, 1538; 
300 – 30000 µg/plate Negative3, 6  (Guzzie and 
Morabit, 1985) 
Valid unpublished GLP-study 
carried out according to US EPA 
test guidelines. 
Ames Test  S. typhimurium TA92, TA98, 
TA100, TA104 
1.9 – 48 µmol/plate 
(190 –4805 µg/plate)7 
Negative
Positive 8 
(Gava et al., 1989) No data on cytotoxicity reported. 
Metabolic activation not reported. 
Due to the limited experimental 
details reported the validity of the 
study cannot be evaluated.  
Modified Ames Test S. typhimurium TA98, TA100, 
TA104;  
E. coli WP2 uvrA/pKM 101 
NR  Negative3   
Positive9 
Positive10 
(Kato et al., 1989) Only abstract reported. Validity of 
the study cannot be evaluated. 
Umu Test  (DNA 
repair test) 
S. typhimurium TA1535/ 
pSK1002 
196, 410, 1235 µg/ml Positive3, 
11,12  
(Ono et al., 1991) Published non-GLP study. 
Unusual study design. Due to the 
limited experimental details and 
results reported the validity of the 
study cannot be evaluated. 
Relevance of results are 
questioned. 
Rec-Assay (DNA 
repair test) 
B. subtilis H17 (Rec+), M45 
(Rec –) 
CR50 Rec+ =209 
μg/ml,  
CR50Rec– = 195 
μg/ml13,2 
CR50 Rec+ =235 
μg/ml,  
CR50Rec– = 173 
μg/ml13,1 
Negative2
Very 
weakly 
positive1 
(Matsui et al., 
1989) 
Insufficient report of study design 
and experimental details. Detailed 
results not reported. Validity of 
the study cannot be evaluated. 
Mitotic aneuploidy 
(DNA repair test) 
S. cerevisiae D61.M 0.74 – 1.96 % (7400 – 
19600µg/ml) 
Negative2  (Zimmermann et 
al., 1985) 
Published non-GLP study. Study 
is considered valid. 
Sister Chromatid Chinese Hamster Ovary Cells ~0.01 – 1.0 µmol/ml Positive  (Gava et al., 1989) Published non-GLP study. Due to 
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Table 12:  Genotoxicity (in vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
Exchange (~1 – 100µg/ml)14 the limited experimental details 
and the incomplete cytotoxicity 
data reported the validity of the 
study cannot be evaluated. 
 Sister Chromatid 
Exchange 
Chinese Hamster Ovary Cells 20, 30, 100 µg/ml  
30, 100, 300 µg/ml 
Positive2, 19  
Positive1, 19 
(Slesinski, 1986) Unpublished GLP study. Study is 
considered valid. 
HGPRT Mutation 
Assay 
Chinese Hamster Ovary Cells 10, 50, 100, 500, 1000 
µg/ml 
 
Negative2, 
15  
Negative1, 
15 
(Slesinski, 1986) Cytotoxic effects at 1 mg/ml. 
Unpublished GLP study. Study is 
considered valid. 
Chromosomal 
Aberrations 
Chinese Hamster Ovary Cells 40 – 120 µg/ml (80, 
100, 120 µg/ml) 
60 – 140 µg/ml (100, 
120, 140 µg/ml) 
Positive2,16, 
20  
Negative1,16 
(Guzzie and 
Morabit, 1986) 
Three highest conentrations 
analysed. Mitotic cell division not 
excessively reduced at 
conentrations used (i.e. not 
cytotoxic). Effects observed were 
chromatid breaks. Good quality 
unpublished GLP study. 
(2,3-Hexanedione [07.018]) Chromosomal 
Malsegregation 
Assay17 
S. cerevisiae D61.M 372 – 833 µg/ml Negative18  (Zimmermann and 
Mohr, 1992) 
Published non-GLP study. Study 
is considered valid. 
(3,4-Hexanedione [07.077]) Ames Test  S. typhimurium TA100 228 – 4900 µg/plate Very 
weakly 
positive2 
(Dorado et al., 
1992) 
Published non-GLP study of good 
quality. 
3-Methylnona-2,4-dione 
[07.184] 
Revere mutation S. typhimurium TA100, 
TA1535, TA98, TA1537 
39, 78, 156, 313, 625 
and 1250 μg/plate 
 
Negative (Sasaki, 2006) Unpublished GLP study. Study 
considered valid 
Revere mutation E. Coli WP2uvrA 39, 78, 156, 313, 625 
and 1250 μg/plate 
 
Negative (Sasaki, 2006) Unpublished GLP study. Study 
considered valid 
Micronucleus Human peripheral lymphocytes 200, 400, 800 and 815 
μg/mL21 
Negative (Watters, 2013) 
 
Valid GLP study, in compliance 
with OECD Guideline 487 
400, 600, and 800 
μg/mL22 
Negative (Watters, 2013) 
 
80, 145, 190 and 210 
μg/mL23 
Negative (Watters, 2013) 
 
Diacetyl-trimer , former 
candidate substance [06.134] 
Revere mutation S. typhimurium TA98, TA100, 
TA102, TA1535, TA1537 
100, 316, 1000, 3160 
or 5000 μg/plate 
Negative3,24
 
(Stien, 2005) Unpublished GLP study. Study 
considered valid 
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Table 12:  Genotoxicity (in vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
 
10, 31.6, 100, 316 or 
1000 μg/plate 
Negative25 
*  Supporting substances are listed in brackets. 
NR = Not reported.  
CR50 = 50 % survival concentrations for the B. subtilis strains. 
1 With metabolic activation.  
2 Without metabolic activation.  
3 With and without metabolic activation.  
4 Estimated from graphical data.  
5 Pure chemical at 28°C, starting titer 14.6 x 106 cells/ml; and pure chemical, cold shock, starting titer 9.1 x 106 cells/ml.  
6 Test substance was cytotoxic at 30000 µg/plate.  
7 Calculated based on molecular weight = 100.12.  
8 Test substance was inactive towards TA92, TA98 and TA100 strains; however, it was mutagenic towards the TA104 strain. 
9 TA104 was positive in the absence of metabolic activation (specific activity = 2.25 revertants/µg); TA92, TA98 and TA100 were negative. 
10 WP2 uvrA/pKM 101 was positive in the presence of metabolic activation (specific activity = 7.73 revertants/μg) and negative in the absence of metabolic activation.  
11 The highest concentration was only used in a 2-hour test (short term reaction) for which weakly positive result were reported.  
12 At 410 µg/ml a strongly positive results was reported after 24 hrs (long term reaction) with S9 metabolic activation, negative results were reported at 410 μg/ml after 2, 4 and 6 hours with S9 
metabolic activation and at 196 µg/ml after 2, 4 and 6 hours and 20 hours in the absence of S9 metabolic activation. 
13 The concentrations indicated are those of the test substance in the interaction period.  
14 Calculated based on molecular weight = 100.12.  
15 Cytotoxicity was observed, with and without S9 metabolic activation, at the 1.0 mg/ml dose level.  
16 Test substance was highly clastogenic in the absence of metabolic activation; however, in the presence of rat-liver S9 metabolic activation it was not clastogenic.  
17 Pure chemical at 28°C, starting titer 10.7 x 106 cells/ml; and pure chemical, cold shock, starting titer 11.3 x 106 cells/ml.  
18 In the pure form the test substance did not induce mitotic chromosome loss; however, almost all of the white colonies scored at the highest concentrations turned out to be respiratory deficient.  
The authors concluded that the test substance induces mitochondrial mutation under these experimental conditions. 
19 Pentan-2,4-dione (purity 99.2 %) was tested for sister chromatid exchange in Chinese hamster ovary (CHO) cells at culture concentrations of 6 to 100 µg/ml without metabolic activation and 
10 to 300 µg/ml with metabolic activation. Experiments were carried out in duplicate. In preliminary experiments the appropriate range of test concentrations was determined for which the 
highest concentration would not kill more than 90% of the treated cells. Cytotoxic effects have been reported at concentrations of ≥1 mg/ml, concentrations above 2 mg/ml were lethal. Result: 
At the highest three doses evaluated for SCE (10, 30 and 100 µgs/ml in the absence and 30, 100 and 300 in the presence of metabolic activation), pentan-2,4-dione produced significant 
(p<0.001) increases in the incidence of SCE in CHO cells both with and without metabolic activation. The SCE increase was greater without metabolic activation than with metabolic 
activation. A steep dose-response relationship was observed without S9, but not with S9. However, reproducible and statistically significant (p<0.001) increases were apparent in both tests. A 
remarkably high increase in the incidence of SCEs, which was higher than the positive control, was observed at 100 µg/ml without metabolic activation..Mitotic inhibition was evident only 
with the 300 µg /ml dose without S9. 
20 Pentan-2,4-dione (purity 99.2 %) was tested in a chromosomal aberration assay in Chinese Hamster Ovary Cells at concentrations of 40–120 µg/ml without metabolic activation and 60-140 
µg/ml with metabolic activation. The three highest concentrations (80, 100 and 120 µg/ml without metabolic activation and 100, 120 and 140 µg/ml with metabolic activation) were analysed 
for chromosomal damage. Preliminary tests performed to assess effects on cell cycle division, indicated that pentan-2,4-dione produced a significant delay in cell division cycle, which was 
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more pronounced in the absence than in the presence of S9. Test concentrations were selected on the basis of cytotoxicity data from preliminary experiments. Result: Statistically significant 
(p>0.001) increases in numbers of chromosome aberrations were observed at the three highest concentrations without S9 activation. However, in the presence of metabolic activation the cells 
tested did not demonstrate increased numbers of chromosome aberrations at any concentrations compared to control values. 
21 Incubation for 3-hour followed by 21-hour recovery period, in the absence of S-9. 
22 Incubation for 3-hour followed by 21-hour recovery period, in the presence of S-9. 
23 Incubation for 24-hour without recovery period, in the absence of S-9. 
24 Standard plate-incorporation method, with and without S9. 
25 Modified pre-incubation method, with and without S9. 
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*  Supporting substances are listed in brackets. 
(a):  Excessive mortality was observed at 400 and 650 mg/kg dose levels; therefore, these dose levels were replaced with 50 and 100 mg/kg.  
(b): Pentan-2,4-dione (purity 99.2 %) was tested in an in vivo Mouse Micronucleus Assay. Swiss Webster Mice (5 animals per sex/dose group) were given i.p. injections of 200, 400 and 650 
mg/kg. Peripheral blood was sampled at 30, 48 and 72 hours post injection. Results: In a dose-finding study using 579-1200 mg/kg toxicity was observed from 694-1200 mg/kg (20 % to 
100 % mortality) and an LD50 of 808 mg/kg i.p. was found (95 % confidential interval 731.6-889.9 mg/ml). In this study, at 48 hours post-injection, PCE/NCE ratio was reduced by 30 % 
and 23 % below the control levels for male and female animals that received a dose of 694 mg/kg, respectively. In the micronucleus study, the PCE/NCE ratio was determined in the 650 
mg/kg group and in controls. No significant or dose-related decrease in the PCE/NCE ratio for either sex at any of the sample times (slight decrease with dose-related trend seen in females 
at 30 hours). In contrast, PCE/NCE ratio at 30 hours was increased over control values in males at 400 and 650 mg/kg. A similar effect was not observed at any concentration at 48 hours. A 
significant decrease in the PCE/NCE ratio (56.5 % of the control) was observed with the positive control. The mean percentages of micronucleated PCEs were 0.38 and 0.22 for the vehicle 
Table 13:  Genotoxicity (in vivo)  
Chemical Name 
[FL-no]* 
Test system Test 
Object 
 
Route Dose Result Refence Comments 
(Diacetyl [07.052]) In vivo Mouse 
Micronucleus 
Assay(bone marrow) 
Mouse Oral 
administration 
300, 600, 1200, 
2400 mg/kg;  
300 mg/kg × 4 
doses 
Negative (Iwata et al., 
1984) 
Published study in Japanese. Results (i.e. 
frequencies of PCEs and micronucleated PCEs, 
including positive and negative controls) are given 
in tables. No information can be found on sampling 
times. Validity of the study cannot be evaluated. 
In vivo Mouse 
Micronucleus Assay 
(bone marrow) 
Mouse Intraperitoneal 
injection 
8, 16, 31, 62, 125, 
250, 500 mg/kg 
Negative (NTP, 1994) Sampling at 24 hours. Only summarised results of 
the study available. The PCE/NCE ratio was not 
reported so it is unclear whether the test substance 
has reached the bone marrow. Relevance of the 
results is limited. 
[Pentan-2,4-dione]  In vivo Mouse 
Micronucleus Assay 
(peripheral blood) 
Mouse Intraperitoneal 
injection 
200, 400, 650 
mg/kg 
Positive (b) (Guzzie and 
Morabit, 1986) 
Sampling at 30, 48, 72 hours. Toxic effects during 
the study not reported (LD50 of 808 mg/kg). 
Unpublished valid GLP-study.  
In vivo Mouse 
Micronucleus Assay 
(bone marrow) 
Mouse Intraperitoneal 
injection 
400, 650 mg/kg Positive (c) (Vergnes and 
Kubena, 
1994a) 
Sampling at 6, 24, 48 hours. Toxic effects during the 
study not reported (LD50 of 808 mg/kg).  
Good quality GLP study carried out according to 
OECD and US EPA guidelines. 
In vivo Rat 
Micronucleus Assay  
(bone marrow) 
Rat Intraperitoneal 
injection 
50, 100, 200 (400, 
650) mg/kg(a) 
Negative (Vergnes and 
Kubena, 
1994b) 
Sampling at 6, 24, 48 hours. Only summarised 
results of the study available.  
Unpublished valid study carried out according to 
EPA standards. Due to the lack of an effect on the 
PCE/NCE ratio it is unclear whether the test 
substance has reached the bone marrow. Relevance 
of the results is limited. 
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control males and 0.12 and 0.14 for the vehicle control females sampled at 30 and 48 hours, respectively. Mean percentages of micronucleated PCEs in CP-treated positive controls were 
2.36 in males and 2.52 in females at 30 hours post-treatment. At 30 hours, a statistically significant increase in the incidence of micronucleated PCE was observed in the peripheral blood at 
400 and 650 mg/kg. The effect was not dose-related. The mean percentages of micronucleated PCEs were 1.42 and 0.80 at 400 mg/kg and 1.16 and 0.80 at 650 mg/kg in males and females, 
respectively. At 48 hours a lower increase in micronucleated PCE than at 30 hours was found at all concentrations tested. As there was no sex-related difference in the micronucleus 
response between males and females sampled at 48 and 72 hours post-treatment, male and female values were combined for statistical analysis. A dose-related and statistically significant 
(p<0.001) increase in the incidence of micronuclei was observed at the 48 hours sample period. A maximum incidence of 0.69 % (3.8 times the vehicle controls) micronucleated PCEs was 
observed for the highest dose level tested. The maximum ratio in the incidences of micronucleated PCEs compared to control was 6.7 (0.80 % at 400 mg/kg at 30 h in females compared to 
0.12 % in control females). At 72 hours the micronucleus response had returned to baseline levels. 
(c): Pentan-2,4-dione (purity >98 %) was tested in an in vivo Mouse Micronucleus Assay. Swiss Webster Mice (5 animals per sex/dose group) were given i.p injections of 400 and 650 mg/kg. 
Bone marrow was sampled 6, 24 and 48 hours post-injection. Results: Serious signs of toxicity were observed in both males and females at 650 mg/kg. Hypoactivity was seen in several 
males and females at 400 mg/kg. No serious signs of toxicity were observed in animals of either sex after day 1. In the micronucleus study, at 6 and 24 hours a significant (p<0.05) increase 
in the PCE/NCE ratio over control values was observed at 400 mg/kg in males. No changes in the PCE/NCE ratio was seen in males at 48 hours in either treatment group and in females of 
either treatment group at any sampling time. The mean percentages of micronucleated PCEs were 0.19, 0.29 and 0.18 for the vehicle control males and 0.20, 0.22 and 0.31 for the vehicle 
control females sampled at 6, 24 and 48 hours, respectively. At 24 hours the incidence of micronucleated PCEs was significantly increased in males and females at 400 and 650 mg/kg. The 
effect was not dose-related. The mean percentages of micronucleated PCEs were 0.81 and 0.97 at 400 mg/kg and 1.32 and 0.80 at 650 mg/kg in males and females, respectively. Mean 
percentages of micronucleated PCEs in CP-treated positive controls at 24 hours post-treatment were 1.47 and 1.63 % in males and females, respectively. The frequency of micronucleated 
PCEs was significantly increased at 24 hours at 400 mg/kg and at 650 mg/kg, both in males and females. A maximum incidence of 1.32 % (4.6 times the vehicle controls) micronucleated 
PCEs was observed for the highest dose level tested. This was also the maximum ratio in the incidences of micronucleated PCEs compared to control (1.32 % at 650 mg/kg at 24 hour in 
males compared to 0.29 % in control males). No significant increase of micronucleated PCEs was observed at 6 and 48 hours at 400 mg/kg and at 650 mg/kg in either sex. 
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APPENDIX A: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the "Procedure", is shown in schematic 
form in Figure A.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed 
on 2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996; JECFA, 1997; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 µg/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products11 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous12 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
11 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated intakes of 
the flavouring agent” (JECFA, 1997). 
12 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated; 
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997). 
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Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
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Figure A1: Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
Flavouring Group Evaluation 11 Revision 3
 
EFSA Journal 2014;12(11):3888 51
APPENDIX B: USE LEVELS / MTAMDI 
B.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table B.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the 
Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is defined 
as the 95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring 
substances (EFFA, 2004a). 
Table B.1.1. Food categories according to Commission Regulation (EC) No 1565/2000 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding 
bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 
01.0 - 15.0 
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The “normal and maximum use levels” are provided by Industry (EFFA, 2003a; EFFA, 2003b; EFFA, 2004b; EFFA, 2007a; EFFA, 2007b; Flavour Industry, 
2005a; Flavour Industry, 2005b) for all the candidate substances in the present flavouring group (Table B.1.2).  
 
Table B.1.2. Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.11Rev3 (EFFA, 2003a; EFFA, 2003b; EFFA, 2004b; EFFA, 2007a; EFFA, 
2007b; Flavour Industry, 2005a; Flavour Industry, 2005b) 
FL-no 
Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.133 7 35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
07.071 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.097 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.152 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.165 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.167 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.168 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.184 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.238 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.248 3 15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.260 3 6 
- 
- 
3 
7 
3 
6 
3 
6 
3 
6 
- 
- 
3 
3 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
3 
6 
3 
6 
- 
- 
- 
- 
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B.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table B.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up.  
Table B2.1.: Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 and reported by the Flavour Industry in the 
following way (see Table B.2.2): 
• Beverages correspond to food category 14.1 
• Foods correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 16  
• Exception a corresponds to food category 5 and 11  
• Exception b corresponds to food category 15 
• Exception c corresponds to food category 14.2  
• Exception d corresponds to food category 12 
• Exception e corresponds to others, e.g. chewing gum. 
Table B2.2.: Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food 
categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, 
pulses and legumes), and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & 
tubers, pulses & legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
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Table B2.2.: Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food 
categories 
Key Food category Food Beverages Exceptions 
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic 
counterparts 
  Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods 
that could not be placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table B.2.3) are presented for all candidate substances in the present 
flavouring group (EFFA, 2003a; EFFA, 2003b; EFFA, 2007b; EFFA, 2004b; Flavour Industry, 2005a; 
Flavour Industry, 2005b);. The mTAMDI values are only given for the highest reported normal use 
levels (see Table B.2.3). 
Table B2.3.: Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
02.133 Butane-2,3-diol 3900 Class I 1800 
07.097 3-(Hydroxymethyl)octan-2-one 1600 Class I 1800 
07.165 4-Hydroxy-4-methylpentan-2-one 1600 Class I 1800 
07.167 4-Hydroxyhexan-3-one 1600 Class I 1800 
07.238 3-Hydroxy-2-octanone 1600 Class I 1800 
07.071 Octane-4,5-dione 1600 Class II 540 
07.152 3,3-Diethoxybutan-2-one 1600 Class II 540 
07.184 3-Methylnona-2,4-dione 1600 Class II 540 
07.248 Octan-2,3-dione 1600 Class II 540 
07.260 1- or 3-Hydroxy-5-methyl-2- or 3-hexanone 1500 Class II 540 
07.168 2-Hydroxypiperitone 1600 Class III 90 
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APPENDIX C: METABOLISM 
C.1 Absorption, Distribution and Elimination 
The candidate substances and supporting substances which are aliphatic acyclic α-diketones 
participate in a keto-enol equilibrium with the corresponding ketoenol (see Figure C.1). The keto form 
predominates (Gordon and Ford, 1972). 
In rats and mice, orally administered acetoin (3-hydroxybutan-2-one [FL-no: 07.051]) is rapidly 
absorbed from the gastrointestinal tract (Gabriel et al., 1972). Upon injection of acetoin-2,3-14C to 
albino rats, 14CO2 appears in the expired air. The average 12 - 20 hours 14CO2 production from acetoin-
2,3-14C was found to be 15 % after intraperitoneal (i.p.) administration (12 hours) and 47.7 % after 
intracardial administration (20 hours) (Gabriel et al., 1972). 
CO2 + OH
O
O
CO2 + H2O
O
O
O
OH
OH
OH
OH
OgluO
Oglu
glucuronosyl
transferase
glucuronosyl
transferase
alpha-hydroxyketonealpha-diketonic 
form
reduction reduction
O
OH
alpha-ketoenolic form
Oglu = O-glucuronic acid
2,3-diol
 
Figure C1: Keto-enol equilibrium and metabolism of aliphatic acyclic and alicyclic α-dicarbonyls 
C.2 Biotransformation 
C.2.1. Hydrolysis 
Ketals are anticipated to be readily hydrolysed after ingestion under the acid conditions in the stomach 
to their corresponding alcohol and ketone prior to absorption. 
In general, esters are hydrolysed to their corresponding alcohol and carboxylic acid. Classes of 
enzymes recognized as carboxylesterases or esterases, the most important of which are the B-
esterases, catalyse hydrolysis. Acetyl esters are the preferred substrates of C-esterases (Heymann, 
1980). In mammals these enzymes occur in most tissues throughout the body (Anders, 1989; 
Heymann, 1980) but predominate in hepatocytes (Heymann, 1980). As an example, it is expected that 
the supporting chemicals, 2-acetoxy-3-butanone and butanon-3-one-2-yl butanoate, are metabolised in 
humans to acetic acid and butanoic acid, respectively, and acetoin. 
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C.2.2. Metabolism of Aliphatic Acyclic Diketones 
The metabolic fate of acyclic aliphatic diketones depends primarily on the position of the carbonyl 
function and the chain length. Aliphatic acyclic diketones and α–hydroxyketones, which contain a 
carbonyl function at the 2-position (i.e. a methyl ketone) may undergo α–hydroxylation and 
subsequent oxidation of the terminal methyl group to eventually yield corresponding ketocarboxylic 
acids. The ketoacids are intermediary metabolites (e.g. α-ketoacids), which may undergo oxidative 
decarboxylation to yield carbon dioxide and an aliphatic carboxylic acid. The acid may be completely 
metabolised in the fatty acid pathway and citric acid cycle (see Figure C.1). β-Keto-acids and 
derivatives readily undergo decarboxylation. Along with α-keto- and α-hydroxyacids, they yield 
breakdown products, which are incorporated into normal biochemical pathways (EFSA, 2005). 
Alternately, the methyl-substituted diketones may be successively reduced to the corresponding 
hydroxyketones and diols, which are excreted in the urine as glucuronic acid conjugates. This pathway 
is favoured at elevated in vivo concentrations, especially for longer chain length ketones. If the 
carbonyl function is located elsewhere on the chain, reduction is the predominant detoxification 
pathway.  
α-Hydroxyketones or their diol metabolites may be excreted as glucuronic acid conjugates (JECFA, 
1999a). 
Acetoin is metabolised primarily via oxidation at low concentrations in vivo and by reduction to 2,3-
butanediol (butane-2,3-diol) at high concentrations. It is estimated that the rat liver is capable of 
oxidising 86 µg (1 µmol) acetoin/g liver per day (Gabriel et al., 1972). 
Oxidation of the terminal methyl group may form an alpha-ketoacid, which undergoes cleavage to 
yield CO2 and a carboxylic acid fragment. 
A total dose of 78 g of acetoin was administered to a dog over a two-month period. The doses were 
given orally in a 3 to 4 percent solution and subcutaneously in a 20 percent solution. 
Urine was collected under toluene from the beginning of the dosing period through 40 hours after the 
last treatment. Butane-2,3-diol was identified as the major urinary excretion product, ranging from 5 to 
25 percent of the dose. The remainder of the dose was completely metabolised (Westerfeld and Berg, 
1943). 
In liver preparations obtained from rats and rabbits, greater than 95 % of the radioactivity of 2,3-14C-
acetoin was detected as a mixture of stereoisomers of butane-2,3-diol (Gabriel et al., 1971). Although 
reductions of diacetyl and acetoin have been observed in animals in vivo and in animal tissue 
preparation in vitro at high concentrations, it appears that oxidation of diacetyl is a major endogenous 
metabolic pathway. 
Reduction of ketones is mediated by alcohol dehydrogenase and NADPH dependent cytosolic 
carbonyl reductases (Bosron and Li, 1980). Reduction of acetoin and diacetyl is catalysed by the 
substrate-specific enzymes diacetyl reductase and acetoin reductase, respectively. In rat liver mince, 
diacetyl, acetoin and butane-2,3-diol are interconvertible (Gabriel et al., 1972). 
In male Wistar albino rats, a single oral dose of 5 mmol diacetyl/kg bw (430 mg diacetyl/kg bw) was 
metabolised by reduction to acetoin, which was present in high concentrations of major organs one 
hour after dosing. The subsequent reduction product, butane-2,3-diol, was detected in the liver, kidney 
and brain. Only 10 minutes incubation time was required to convert 10 nmol (9 x 10-4 mg) diacetyl to 
3.7 nmol (3 x 10-4 mg) acetoin and 6.3 nmol (6 x 10-4 mg) butane-2,3-diol in rat liver homogenate 
(Otsuka et al., 1996). The organ-specific reductase activity was greatest in the liver and least in the 
brain (Otsuka et al., 1996). 
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Diacetyl and acetoin are reported to be endogenously formed in cats when pyruvate is converted to 
diacetyl and acetoin by pyruvate decarboxylase (Gabriel et al., 1972). Mean fasting blood acetoin 
levels of approximately 100 µg acetoin/100 ml blood have been reported (Dawson and Hullin, 1954). 
Pyruvate also forms diacetyl in vitro in rat liver preparations (Järnefelt, 1955) and in microorganisms 
(Juni and Heym, 1956). 
Diacetyl, acetoin and butane-2,3-diol are also reported to be endogenous in humans at levels of 0.25 -
 0.75 microM, 2.2 microM and 5 - 10 microM, respectively, in plasma. Plasma levels of diacetyl and 
acetoin, precursors of butane-2,3-diol were not affected by ethanol consumption, whereas plasma 
levels of butane-2,3-diol were elevated in individuals defective in aldehyde dehydrogenase (Otsuka et 
al., 1999) showing that acetoin is rapidly reduced to butan-2,3-diol in humans. 
C.3  Studies on Candidate Substances 
Butane-2,3-diol [FL-no: 02.133]: 
Diacetyl, acetoin and butane 2,3-diol have been reported to be endogeous in humans. Higher levels of 
butane-2,3-diol, but not of diacetyl and acetoin were found in blood and urine of individuals defective 
in aldehyde dehydrogenase compared to normal individuals. This suggest that acetaldehyde formed 
from ethanol is converted to diacetyl, acetoin and eventually to butane-2,3-diol (Otsuka et al., 1999). 
The metabolic interrelationship of these chemicals is discussed above. Butane-2,3-diol may be an 
intermediate in the mammalian metabolism of acetaldehyde in vitro, and butane-2,3-diol and its 
oxidation metabolite, acetoin, have been reported as intermediates in the mammalian metabolism of 
pyruvate in vitro (Veech et al., 1987; Montgomery et al., 1993). 
Butane-2,3-diol, 2-butanol and 3-hydroxy-2-butanone were identified as metabolites in the serum of 
guinea pigs injected i.p. with methyl ethyl ketone. 3-Hydroxy-2-butanone forms by alpha-
hydroxylation of methyl ethyl ketone that subsequently forms butane-2,3-diol by reduction of the 
ketone function. The half-life of methyl ethyl ketone in serum was 270 minutes, and the clearance time 
of butane-2,3-diol was 16 hours (DiVincenzo et al., 1976). A proposed pathway of butane-2,3-diol 
elimination is as 2,3-butanediol β-glucuronide after coupling with UDP-glucuronyltransferase (Otsuka 
et al., 1999). 
4-Hydroxy-4-methylpentan-2-one [FL-no: 07.165]: 
4-Hydroxy-4-methylpentan-2-one and 4-methyl-2-pentanol were detected in serum after i.p. injection 
of 4-methyl-2-pentanone to guinea pigs. 4-Hydroxy-4-methylpentan-2-one was the principal 
metabolite and was cleared in 16 hours. The concentration of 4-methyl-2-pentanol was too low for 
quantification. 4-Methyl-2-pentanone is metabolised by oxidation at the omega-1 carbon atom to form 
the hydroxylated ketone, 4-hydroxy-4-methylpentan-2-one, and to a lesser extent by reduction of the 
carbonyl group to form the secondary alcohol, 4-methyl-2-pentanol (DiVincenzo et al., 1976). 
Pentan-2,4-dione: 
Pentan-2,4-dione was investigated for its comparative pharmacokinetics in male F344 rats (4/1 group) 
by single intravenous (i.v.) injection of 4.3, 43, 148.5 and 430 mg/kg bw, or a 6-hour nose only 
inhalation exposure to 14C-pentan-2,4-dione. Only the i.v. part of the study is reported here. The 
plasma concentration of 14C-pentan-2,4-dione derived radioactivity declined in a biexponential 
fashion. The 14C plasma concentration-time curves and derived pharmacokinetic parameters indicated 
that dose-linear kinetics occurred in the i.v. dose range of 4.3 to 148.5 mg/kg, but not at 430 mg/kg. 
Metabolism of pentan-2,4-dione was rapid in that the concentration of unmetabolised pentan-2,4-dione 
declined steadily to undetectable levels after eight hours. 14C-pentan-2,4-dione derived radioactivity 
was eliminated mainly as exhaled 14CO2 and in the urine. In the 48-hour samples for the 4.3, 43 and 
148.5 mg/kg doses, 14CO2 elimination was constant at 36.8, 38.8 and 42.3 %, and greater than the 
urinary 14C excretion of 17.9, 14.3 and 29.6 %, respectively. However, at the 430 mg/kg i.v. dose there 
was a reversal of the excretion pattern, with the urine 14C excretion (54.7 %) becoming greater than the 
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exhaled 14CO2 (27.3 %). Free parent compound and seven metabolites were detected in the 12-hour 
urine samples. In the 24 - 48-hour urine samples only one metabolite was detectable in small amounts 
(Frantz et al., 1998). At lower dose levels oxidation predominates, whereas at the high dose urinary 
hydroxylated metabolites formed by hydroxylation and ketone reduction predominate. These 
mechanisms are similar to those observed for diacetyl.  
C.4  Conclusions on Metabolism 
It is anticipated that humans will metabolise aliphatic acyclic methyl ketones principally by oxidation 
of the terminal methyl group at low levels of exposure. At higher levels, reduction to the diol and 
subsequent conjugation with glucuronic acid is a competing detoxification pathway. Other aliphatic 
acyclic diketones and hydroxyketones are reduced, conjugated with glucuronic acid and excreted. The 
ketals in the present FGE are anticipated to be hydrolysed to the corresponding alcohols and ketones.  
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
DMSO  Dimethyl sulphoxide 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
GLP  Good Laboratory Practice 
GSH  Glutathione 
FLAVIS (FL) Flavour Information System (database) 
HPLC  High-performance liquid chromatography 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IP   Intraparenteral 
IR   Infrared spectroscopy 
IV   Intravenous 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MNBN  Micronucleated binucleate cells 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
MTS  Minimum Toxicity Screen 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
NMR  Nuclear magnetic resonance 
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No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PHA  Phytohaemagglutinin 
RI   Replication Index 
SC  Structural class 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDP  Uridine DiPhosphate 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organization  
 
